(0)
The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1
The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS
Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod s efficacy and safety
1,2,3
Approval builds on Janssen s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS
Janssen, the Pharmaceutical Companies of Johnson Johnson, announced today that the European Commission (EC) has approved PONVORY ?
(ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.